Lower synaptic density is associated with depression severity and network alterations.

Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, Sanacora G, Krystal JH, Carson RE, Esterlis I. · 2019

Read Lower synaptic density is associated with depression severity and network alterations. by Holmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, Sanacora G, Krystal JH, Carson RE, Esterlis I. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6449365.txt.

Introduction

Holmes and co-authors scan living brains for synaptic density in depression and PTSD, the first test of whether synapse loss tracks symptoms in people rather than in post-mortem tissue. PET imaging with the SV2A tracer UCB-J estimated nerve terminal numbers in 26 unmedicated patients with depression, PTSD, or both, plus 21 healthy controls.

Depression severity ran opposite to synaptic density: the most depressed patients showed clearly lower SV2A signal than controls. Density also tracked abnormal functional connectivity measured by MRI, tying structural loss to network disruption. The results give treatment developers a measurable target, since therapies that rebuild synaptic connections should move this marker if they work.

Catalog record

CREATORHolmes SE, Scheinost D, Finnema SJ, Naganawa M, Davis MT, DellaGioia N, Nabulsi N, Matuskey D, Angarita GA, Pietrzak RH, Duman RS, Sanacora G, Krystal JH, Carson RE, Esterlis I.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE61 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6449365

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Lower synaptic density is associated with depression severity and network alterations By Sophie E. Holmes, Dustin Scheinost, Sjoerd J. Finnema, Mika Naganawa, Margaret T. Davis, Nicole DellaGioia, Nabeel Nabulsi, David Matuskey, Gustavo A. Angarita, Robert H. Pietrzak, Ronald S. Duman, Gerard Sanacora Published in: Nature Communications DOI: 10.1038/s41467-019-09562-7 ABSTRACT Synaptic loss and deficits in functional connectivity are hypothesized to contribute to symptoms associated with major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The synaptic vesicle glycoprotein 2A (SV2A) can be used to index the number of nerve terminals, an indirect estimate of synaptic density. Here, we used positron emission tomography (PET) with the SV2A radioligand [11C]UCB-J to examine synaptic density in n = 26 unmedicated individuals with MDD, PTSD, or comorbid MDD/PTSD. The severity of depressive symptoms was inversely correlated with SV2A density, and individuals with high levels of depression showing lower SV2A density compared to healthy controls (n = 21). SV2A density was also associated with aberrant network function, as measured by magnetic resonance imaging (MRI) functional connectivity. This is the first in vivo evidence linking lower synaptic density to network alterations and symptoms of depression. Our findings provide further incentive to evaluate interventions that restore synaptic connections to treat depression. INTRODUCTION The human brain displays remarkable neuroplasticity in response to stress. Persisting high levels of stress are thought to result in loss of synapses in circuits underlying affective and cognitive processes1. These reductions are presumed to contribute to the symptoms of depression associated with major depressive disorder (MDD) and post-traumatic stress disorder (PTSD)—highly comorbid disorders that may have shared neurobiological underpinnings2,3. Synaptic deficits are evident in MDD and might contribute to the neurobiology of PTSD. For example, post-mortem research has demonstrated lower number of synapses, and corresponding lower expression of synaptic-function-related genes in the dorsolateral prefrontal cortex (dlPFC) of individuals with MDD4, consistent with evidence of lower levels of synaptic signaling proteins in MDD4–6. Preliminary evidence also points to synaptic deficits in PTSD7,8, although post-mortem studies in PTSD are lacking. Brain imaging studies have consistently shown lower brain volume in the PFC, anterior cingulate cortex (ACC) and the hippocampus in both MDD9,10 and PTSD11, likely in part due to synaptic and neuronal loss1. Stress-related alterations in synaptic connections are also thought to underlie network dysfunction, with functional magnetic resonance imaging (fMRI) studies indicating disrupted functional connectivity within the PFC and its target limbic regions, as well as in wider brain networks in both MDD12–14 and PTSD15. Stress-induced alterations in synaptic connections and resultant network dysfunction likely underlie both cognitive and affective deficits in these disorders. Preclinical studies provide further evidence of lower synaptic density in models of chronic stress and depression, specifically in PFC and hippocampal regions16–18. Synaptic deficits in depression and PTSD may be a target for treatment. For example, ketamine (an NMDA receptor antagonist with fast-acting antidepressant properties) rapidly increases the number and function of synaptic connections in preclinical models of chronic stress and produces rapid antidepressant-like effects16,19. Evidence of a functional association between synapse loss and depression is provided by studies demonstrating that inhibition of synaptic protein synthesis, resulting in a reduction in synapse number in the medial PFC, causes depressive-like behaviors in rodent models20. Further, depressed individuals, who exhibit deficits in cortical functional connectivity14,21, display increased PFC connectivity during ketamine infusion22 and 24 hours later22,23. Enhancing synaptic connectivity and plasticity might, therefore, restore executive control over emotions in stress disorders such as MDD and PTSD. That increasing synaptic connections reverses depressive-like behavior in animal models19,24, and may underlie the therapeutic effects of ketamine in MDD25,26 and PTSD27, provides further support for the theory that synaptic loss may contribute to the neurobiology underlying depressive symptoms in these disorders, which are often resistant to conventional antidepressants. However, synaptic density has not yet been studied in living humans with MDD and PTSD, and has, until now, been confined to small cohort post-mortem and preclinical quantification. In vivo estimates of synaptic density are now possible with the development of [11C]UCB-J—a radioligand that binds to the synaptic vesicle glycoprotein 2A (SV2A). SV2A is ubiquitously and homogenously located in synapses across the brain28. The number of vesicles per nerve terminal is a stable feature of neurons - the synaptic vesicle pool size is rapidly replenished during neural activity to sustain the capacity for ongoing neurotransmitter release29. Therefore, radioligand binding to SV2A provides an estimate of the density of nerve terminals and can serve as a proxy for the quantification of synaptic density. Our validation studies show that post-mortem quantification of SV2A is highly correlated with the commonly used synaptic density marker synaptophysin and that in vivo binding of [11C]UCB-J PET is highly correlated with post-mortem SV2A density30. [11C]UCB-J also has excellent imaging properties, including high specificity, rapid kinetics, high test-retest reproducibility and the ability to produce high-quality parametric maps30,31. Further, PET imaging of SV2A has already been shown to be sensitive to lower synaptic density in temporal lobe epilepsy30 and Alzheimer’s disease32. [11C]UCB-J PET, therefore, provides a unique opportunity to investigate synaptic density across MDD and PTSD. Given the heterogeneity of mental disorders, it is now recognized that mapping transdiagnostic symptoms to their underlying neurobiology and brain circuitry may have a greater translational impact than attempting to identify targets for categorical disorders33. We therefore adopted a transdiagnostic approach in an effort to move beyond categorical diagnoses and explored whether a shared neurobiological substrate, namely lower synaptic density, could underlie the symptomatic overlap between MDD and PTSD, which could help to inform a more targeted, symptom-based approach to treating these debilitating disorders. Specifically, we present results of the first known in vivo investigation of synaptic density and its association with depressive symptoms and cognitive function in a transdiagnostic sample of unmedicated individuals with MDD, PTSD and healthy comparison (HC) subjects using [11C]UCB-J and PET. Our primary hypothesis was that synaptic density, as measured by [11C]UCB-J PET, would be negatively associated with severity of depressive symptoms transdiagnostically. We examined synaptic density in the dlPFC, ACC and hippocampus based on the existing literature indicating alterations in synaptic function and decreased tissue volume in relation to chronic stress, MDD and PTSD within these regions9–11,34–36. Loss of synaptic connections is likely to have consequences for network organization and function. Therefore, as a secondary analysis, we examined intrinsic connectivity distribution (ICD)37, a measure of whole-brain connectivity in regions of interest, and used follow-up seed connectivity to explore network alterations in relation to synaptic density, symptom severity, and cognitive function. We also stratified clinical subjects by depression severity (HAMD-17 score of 14; moderate severity38) for further group comparisons. We report the first known evidence for a relationship between synaptic density and depression in vivo. We show that lower synaptic density is associated with higher severity depressive symptoms, and that individuals with high severity symptoms exhibit lower synaptic density compared to healthy controls and individuals with low severity depression. We also demonstrate that synaptic density is associated with network alterations. Findings from this study provide further incentive to evaluate interventions that restore synaptic connections to treat depression. RESULTS Synaptic density and depressive symptoms [11C]UCB-J VT, indicative of SV2A (synaptic) density, was significantly negatively correlated with severity of depressive symptoms (HAMD-17) across all clinical subjects in dlPFC (r

Read the complete text